human bca cell lines umuc3  (Procell Inc)

Journal: Molecular imaging and biology

Article Title: EGFR-targeted immunoPET of UMUC3 orthotopic bladder tumors

doi: 10.1007/s11307-022-01708-2

Figure Lengend Snippet: (A) Western blot analysis of EGFR protein levels in RT112, T24, UMUC3, and UMUC14 bladder cancer cell lines. (B, C) 89Zr-labeled Panitumumab binding to EGFR-expressing UMUC3 bladder cancer cells in the absence (B) and presence (C) of excess Panitumumab. UMUC3 bladder cancer cells (1, 2, 4, or 10 million) were incubated with 37 KBq of [89Zr]Zr-DFO-Panitumumab (0.33–0.36 μg) for 1 h at 4°C. For blocking of 89Zr-labeled Panitumumab binding to cancer cells, cells were incubated with 89Zr-labeled Panitumumab in the presence of 33–36 μg DFO-Panitumumab. Data are presented as mean ± S.E.M, n = 6 (2 independent experiments). (D) UMUC3 cells were incubated with [89Zr]Zr-DFO-Panitumumab (0–125 nM) for 3 h at 4°C. Specific binding of [89Zr]Zr-DFO-Panitumumab and non-linear regression curve fit are represented in black spheres and dotted lines. Data are presented as mean ± S.E.M, n = 3.

Article Snippet: Bladder cancer cell lines, cell culture, and Western blot Human BCa cell lines UMUC3, RT112, T24, and UMUC4 were obtained from the American Type Culture Collection (ATCC Manassas, VA), Sigma-Aldrich, or the German Collection of Microorganisms and Cell Cultures.

Techniques: Western Blot, Labeling, Binding Assay, Expressing, Incubation, Blocking Assay

Journal: Molecular imaging and biology

Article Title: EGFR-targeted immunoPET of UMUC3 orthotopic bladder tumors

doi: 10.1007/s11307-022-01708-2

Figure Lengend Snippet: (A) Representative coronal PET images and (B) biodistribution data of [89Zr]Zr-DFO-Panitumumab in athymic nude mice bearing subcutaneous UMUC3 tumors. PET images and biodistribution were performed at 72 h after tail vein injection of [89Zr]Zr-DFO-Panitumumab (8.25–9.18 MBq, 58–65 μg protein). Bars, n = 4 mice per group, mean ± S.E.M. (C) 89Zr-labeled IgG or 89Zr-labeled Panitumumab accumulation in UMUC3 subcutaneous tumors. Tumors were collected at 72 h after tail vein injection of [89Zr]Zr-DFO-Panitumumab or [89Zr]Zr-DFO-IgG (8.25–9.18 MBq, 58–65 μg protein). Blocking experiments were performed by administering [89Zr]Zr-DFO-Panitumumab in the presence of 2.32 mg DFO-Panitumumab. Data are presented as mean ± S.E.M, n = 4 mice per group. **P < 0.01, based on a Student’s t-test. %ID/g, percentage of injected dose per gram.

Article Snippet: Bladder cancer cell lines, cell culture, and Western blot Human BCa cell lines UMUC3, RT112, T24, and UMUC4 were obtained from the American Type Culture Collection (ATCC Manassas, VA), Sigma-Aldrich, or the German Collection of Microorganisms and Cell Cultures.

Techniques: Injection, Labeling, Blocking Assay

Journal: Molecular imaging and biology

Article Title: EGFR-targeted immunoPET of UMUC3 orthotopic bladder tumors

doi: 10.1007/s11307-022-01708-2

Figure Lengend Snippet: (A) Schematic of PET imaging and biodistribution studies of [89Zr]Zr-DFO-Panitumumab in orthotopic UMUC3 tumors. Right panel shows representative ultrasound images of murine bladders at 11 days after UMUC3 cells’ implantation in the bladder. (B) Representative coronal and MIP PET images of [89Zr]Zr-DFO-Panitumumab in athymic nude mice bearing orthotopic UMUC3 tumors or mice without tumors (M1, M2, M5, and M6 are mouse identifications of 2 mice included in the respective cohorts). PET images were collected at 72 h after tail vein injection of [89Zr]Zr-DFO-Panitumumab (8.25–9.18 Mq, 58–65 μg protein). %ID/g, percentage of injected dose per gram.

Article Snippet: Bladder cancer cell lines, cell culture, and Western blot Human BCa cell lines UMUC3, RT112, T24, and UMUC4 were obtained from the American Type Culture Collection (ATCC Manassas, VA), Sigma-Aldrich, or the German Collection of Microorganisms and Cell Cultures.

Techniques: Imaging, Injection

Journal: Molecular imaging and biology

Article Title: EGFR-targeted immunoPET of UMUC3 orthotopic bladder tumors

doi: 10.1007/s11307-022-01708-2

Figure Lengend Snippet: (A) Biodistribution data of [89Zr]Zr-DFO-Panitumumab in athymic nude mice without tumors (top panel, labeled as M5-M8 where each bar represents an individual mouse) or with UMUC3 orthotopic tumors (bottom panel, labeled as M1-M4 where each bar represents an individual mouse). Biodistribution was performed at 72 h after tail vein injection of [89Zr]Zr-DFO-Panitumumab (8.25–9.18 MBq, 58–65 μg protein). Each bar represents data collected for one mouse of each cohort. (B) Bladder tumors at 14 days after UMUC3 cells’ implantation in the bladder. (C) 89Zr-labeled Panitumumab accumulation in UMUC3 orthotopic tumors or non-tumor bladders at 14 days after UMUC3 cells’ implantation in the bladder. Bladders were collected at 72 h after tail vein injection of [89Zr]Zr-DFO-Panitumumab (8.25–9.18 MBq, 58–65 μg protein). Data are presented as mean ± S.E.M, n = 4 mice per group. *P < 0.05, based on a Student’s t-test. (D) EGFR protein levels in UMUC3 orthotopic bladder tumors. Tumors were collected and EGFR expression analyzed by western blot for mice labeled as M1, M2, M3, and M4. β-actin is a loading control.

Article Snippet: Bladder cancer cell lines, cell culture, and Western blot Human BCa cell lines UMUC3, RT112, T24, and UMUC4 were obtained from the American Type Culture Collection (ATCC Manassas, VA), Sigma-Aldrich, or the German Collection of Microorganisms and Cell Cultures.

Techniques: Labeling, Injection, Expressing, Western Blot, Control

Journal: Molecular imaging and biology

Article Title: EGFR-targeted immunoPET of UMUC3 orthotopic bladder tumors

doi: 10.1007/s11307-022-01708-2

Figure Lengend Snippet: (A) Western blot analysis of EGFR protein levels in RT112, T24, UMUC3, and UMUC14 bladder cancer cell lines. (B, C) 89Zr-labeled Panitumumab binding to EGFR-expressing UMUC3 bladder cancer cells in the absence (B) and presence (C) of excess Panitumumab. UMUC3 bladder cancer cells (1, 2, 4, or 10 million) were incubated with 37 KBq of [89Zr]Zr-DFO-Panitumumab (0.33–0.36 μg) for 1 h at 4°C. For blocking of 89Zr-labeled Panitumumab binding to cancer cells, cells were incubated with 89Zr-labeled Panitumumab in the presence of 33–36 μg DFO-Panitumumab. Data are presented as mean ± S.E.M, n = 6 (2 independent experiments). (D) UMUC3 cells were incubated with [89Zr]Zr-DFO-Panitumumab (0–125 nM) for 3 h at 4°C. Specific binding of [89Zr]Zr-DFO-Panitumumab and non-linear regression curve fit are represented in black spheres and dotted lines. Data are presented as mean ± S.E.M, n = 3.

Article Snippet: Human BCa cell lines UMUC3, RT112, T24, and UMUC4 were obtained from the American Type Culture Collection (ATCC Manassas, VA), Sigma-Aldrich, or the German Collection of Microorganisms and Cell Cultures.

Techniques: Western Blot, Labeling, Binding Assay, Expressing, Incubation, Blocking Assay

Journal: Molecular imaging and biology

Article Title: EGFR-targeted immunoPET of UMUC3 orthotopic bladder tumors

doi: 10.1007/s11307-022-01708-2

Figure Lengend Snippet: (A) Representative coronal PET images and (B) biodistribution data of [89Zr]Zr-DFO-Panitumumab in athymic nude mice bearing subcutaneous UMUC3 tumors. PET images and biodistribution were performed at 72 h after tail vein injection of [89Zr]Zr-DFO-Panitumumab (8.25–9.18 MBq, 58–65 μg protein). Bars, n = 4 mice per group, mean ± S.E.M. (C) 89Zr-labeled IgG or 89Zr-labeled Panitumumab accumulation in UMUC3 subcutaneous tumors. Tumors were collected at 72 h after tail vein injection of [89Zr]Zr-DFO-Panitumumab or [89Zr]Zr-DFO-IgG (8.25–9.18 MBq, 58–65 μg protein). Blocking experiments were performed by administering [89Zr]Zr-DFO-Panitumumab in the presence of 2.32 mg DFO-Panitumumab. Data are presented as mean ± S.E.M, n = 4 mice per group. **P < 0.01, based on a Student’s t-test. %ID/g, percentage of injected dose per gram.

Article Snippet: Human BCa cell lines UMUC3, RT112, T24, and UMUC4 were obtained from the American Type Culture Collection (ATCC Manassas, VA), Sigma-Aldrich, or the German Collection of Microorganisms and Cell Cultures.

Techniques: Injection, Labeling, Blocking Assay

Journal: Molecular imaging and biology

Article Title: EGFR-targeted immunoPET of UMUC3 orthotopic bladder tumors

doi: 10.1007/s11307-022-01708-2

Figure Lengend Snippet: (A) Schematic of PET imaging and biodistribution studies of [89Zr]Zr-DFO-Panitumumab in orthotopic UMUC3 tumors. Right panel shows representative ultrasound images of murine bladders at 11 days after UMUC3 cells’ implantation in the bladder. (B) Representative coronal and MIP PET images of [89Zr]Zr-DFO-Panitumumab in athymic nude mice bearing orthotopic UMUC3 tumors or mice without tumors (M1, M2, M5, and M6 are mouse identifications of 2 mice included in the respective cohorts). PET images were collected at 72 h after tail vein injection of [89Zr]Zr-DFO-Panitumumab (8.25–9.18 Mq, 58–65 μg protein). %ID/g, percentage of injected dose per gram.

Article Snippet: Human BCa cell lines UMUC3, RT112, T24, and UMUC4 were obtained from the American Type Culture Collection (ATCC Manassas, VA), Sigma-Aldrich, or the German Collection of Microorganisms and Cell Cultures.

Techniques: Imaging, Injection

Journal: Molecular imaging and biology

Article Title: EGFR-targeted immunoPET of UMUC3 orthotopic bladder tumors

doi: 10.1007/s11307-022-01708-2

Figure Lengend Snippet: (A) Biodistribution data of [89Zr]Zr-DFO-Panitumumab in athymic nude mice without tumors (top panel, labeled as M5-M8 where each bar represents an individual mouse) or with UMUC3 orthotopic tumors (bottom panel, labeled as M1-M4 where each bar represents an individual mouse). Biodistribution was performed at 72 h after tail vein injection of [89Zr]Zr-DFO-Panitumumab (8.25–9.18 MBq, 58–65 μg protein). Each bar represents data collected for one mouse of each cohort. (B) Bladder tumors at 14 days after UMUC3 cells’ implantation in the bladder. (C) 89Zr-labeled Panitumumab accumulation in UMUC3 orthotopic tumors or non-tumor bladders at 14 days after UMUC3 cells’ implantation in the bladder. Bladders were collected at 72 h after tail vein injection of [89Zr]Zr-DFO-Panitumumab (8.25–9.18 MBq, 58–65 μg protein). Data are presented as mean ± S.E.M, n = 4 mice per group. *P < 0.05, based on a Student’s t-test. (D) EGFR protein levels in UMUC3 orthotopic bladder tumors. Tumors were collected and EGFR expression analyzed by western blot for mice labeled as M1, M2, M3, and M4. β-actin is a loading control.

Article Snippet: Human BCa cell lines UMUC3, RT112, T24, and UMUC4 were obtained from the American Type Culture Collection (ATCC Manassas, VA), Sigma-Aldrich, or the German Collection of Microorganisms and Cell Cultures.

Techniques: Labeling, Injection, Expressing, Western Blot, Control